Idorsia

Global Expansion And FDA Review Will Moderate Overvaluation

AnalystConsensusTarget

Not Invested

Consensus Narrative from 1 Analyst

Published

08 Sep 25

AnalystConsensusTarget's Fair Value

CHF 2.00

80.8% overvalued

08 Sep

CHF 3.62

119.8%

25.5%

119.8%

25.5%

Edit anytime before Sep 8 8:13 PM. Then post Updates to your followers.

Author's Valuation

CHF 2.0

80.8% overvalued

AnalystConsensusTarget Fair Value

Narrative

Updates0

AnalystConsensusTarget Fair Value

CHF 2.0

80.8% overvalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

19.00%

Biotech revenue growth rate

7.65%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

6.50%

Calculation

CHF 72.57m

Earnings '28

8.70x

PE Ratio '28

CHF 631.07m

Market Cap '28

CHF 631.07m

Market Cap '28

259.82m

No. shares '28

CHF 2.43

Share Price '28

CHF 2.43 Share Price '28

Discounted to 2025 @ 7.22% p.a.

CHF 1.97

Fair Value '25